{
    "Trade/Device Name(s)": [
        "Randox RX Daytona Plus Alkaline Phosphatase (ALP)"
    ],
    "Submitter Information": "Randox Laboratories Limited",
    "510(k) Number": "K162275",
    "Predicate Device Reference 510(k) Number(s)": [
        "K991576"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CJE"
    ],
    "Summary Letter Date": "March 21, 2017",
    "Summary Letter Received Date": "March 23, 2017",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1050"
    ],
    "Regulation Name(s)": [
        "Alkaline phosphatase or isoenzymes test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Alkaline Phosphatase (ALP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "RX Daytona Plus"
    ],
    "Method(s)/Technology(ies)": [
        "Colorimetric method (IFCC)"
    ],
    "Methodologies": [
        "Colorimetric measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Randox RX Daytona Plus Alkaline Phosphatase (ALP) assay for quantitative measurement of ALP activity in serum and lithium heparin plasma.",
    "Indications for Use Summary": "For quantitative in vitro determination of alkaline phosphatase activity in serum and lithium heparinized plasma to aid diagnosis, treatment, and investigation of hepatobiliary and bone disease.",
    "fda_folder": "Clinical Chemistry"
}